CA3206959A1 - Methods for treating and ameliorating cancer - Google Patents

Methods for treating and ameliorating cancer Download PDF

Info

Publication number
CA3206959A1
CA3206959A1 CA3206959A CA3206959A CA3206959A1 CA 3206959 A1 CA3206959 A1 CA 3206959A1 CA 3206959 A CA3206959 A CA 3206959A CA 3206959 A CA3206959 A CA 3206959A CA 3206959 A1 CA3206959 A1 CA 3206959A1
Authority
CA
Canada
Prior art keywords
optionally
leukemia
aml
drug
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3206959A
Other languages
English (en)
French (fr)
Inventor
Catriona Jamieson
Leslie CREWS ROBERTSON
Michael Burkart
Larisa Balaian
Phoebe MONDALA
Cayla MASON
Raymond H. DIEP
James LACLAIR
Thomas WHISENANT
Warren C. Chan
Inge VAN DER WERF
Peggy Wentworth
Wenxue MA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CA3206959A1 publication Critical patent/CA3206959A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3206959A 2021-02-01 2022-02-01 Methods for treating and ameliorating cancer Pending CA3206959A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163144378P 2021-02-01 2021-02-01
US63/144,378 2021-02-01
PCT/US2022/014663 WO2022165398A1 (en) 2021-02-01 2022-02-01 Methods for treating and ameliorating cancer

Publications (1)

Publication Number Publication Date
CA3206959A1 true CA3206959A1 (en) 2022-08-04

Family

ID=82654982

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3206959A Pending CA3206959A1 (en) 2021-02-01 2022-02-01 Methods for treating and ameliorating cancer

Country Status (7)

Country Link
US (1) US20240148688A1 (https=)
EP (1) EP4284519A4 (https=)
JP (2) JP2024506847A (https=)
CN (1) CN116829142A (https=)
AU (1) AU2022214463A1 (https=)
CA (1) CA3206959A1 (https=)
WO (1) WO2022165398A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024254465A2 (en) * 2023-06-09 2024-12-12 The Regents Of The University Of California Methods for promoting expansion of human cd34+ cells in vivo and for promoting neural regeneration

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04352783A (ja) * 1991-05-27 1992-12-07 Taisho Pharmaceut Co Ltd １２員環マクロライド系化合物
US5846743A (en) 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
US6589503B1 (en) 1998-06-20 2003-07-08 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US20040151766A1 (en) 2003-01-30 2004-08-05 Monahan Sean D. Protein and peptide delivery to mammalian cells in vitro
WO2005063156A1 (en) 2003-12-22 2005-07-14 Shear/Kershman Laboratories, Inc. Oral peptide delivery system with improved bioavailability
JP3903061B2 (ja) 2003-12-24 2007-04-11 株式会社Ｌｔｔバイオファーマ 薬物を含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる非経口投与用製剤
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
JP4758915B2 (ja) 2004-08-06 2011-08-31 バイオスペクトラム，インコーポレイテッド 多重層リポソームおよびその製造方法
ATE493444T1 (de) 2004-10-18 2011-01-15 Nitto Denko Corp Intrazelluläre peptidabgabe
US9005654B2 (en) 2005-07-27 2015-04-14 Protiva Biotherapeutics, Inc. Systems and methods for manufacturing liposomes
WO2007110704A2 (en) * 2005-09-28 2007-10-04 Novimmune Sa Macrolide compositions as therapeutic agent
SG10201903112WA (en) * 2013-04-08 2019-05-30 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
US10675267B2 (en) * 2015-09-23 2020-06-09 The Regents Of The University Of California Methods for detection and eradication of myeloid leukemia stem cells
WO2019148101A1 (en) 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
JP2024504367A (ja) * 2021-01-22 2024-01-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア がんを治療及び改善するための方法

Also Published As

Publication number Publication date
EP4284519A1 (en) 2023-12-06
EP4284519A4 (en) 2024-12-25
JP2024506847A (ja) 2024-02-15
AU2022214463A1 (en) 2023-09-14
CN116829142A (zh) 2023-09-29
JP2025065209A (ja) 2025-04-17
US20240148688A1 (en) 2024-05-09
WO2022165398A1 (en) 2022-08-04

Similar Documents

Publication Publication Date Title
KR102301175B1 (ko) 항종양 알칼로이드를 이용한 병용요법
JP7047148B2 (ja) 骨髄腫を治療するためのセルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）
JP2019116517A (ja) リポソームイリノテカンを含む併用療法を用いた、膵臓癌を治療するための方法
JP2012520299A (ja) キナーゼタンパク質結合阻害剤
WO2019126739A1 (en) Pyrvinium pamoate anti-cancer therapies
HK1221638A1 (zh) 使用辅酶q10联合疗法治疗癌症
CN116635009A (zh) 用于递送抗癌剂的具有改进的治疗指数的组合物和方法
EA032345B1 (ru) Способ лечения рака с использованием кофермента q10
WO2019109074A1 (en) Mebendazole cancer therapies and methods of use
US11969396B2 (en) IPA-3-loaded liposomes and methods of use thereof
CN116848094A (zh) 叔胺类脂质化合物及其应用
KR20140040728A (ko) Pi3k 억제제 화합물을 사용한 중피종 치료 방법
JP2025065209A (ja) がんを処置および改善するための方法
US9012422B2 (en) Method of treating acute myelogenous leukemia
Mattern-Schain et al. Cell mimetic liposomal nanocarriers for tailored delivery of vascular therapeutics
KR102569052B1 (ko) 암의 치료를 위한 약제학적 조합물
CN113272281A (zh) 用于治疗骨髓增生异常综合征的alk5抑制剂
ES2809460T3 (es) Nuevo método de producción de lipoplejo para administración local y fármaco antitumoral que utiliza lipoplejo
US20220016118A1 (en) Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof
CN102215833B (zh) 苯醌衍生物e3330联合化疗剂用于治疗癌症和血管生成
US20250339539A1 (en) Phosphate Membrane Nanodiscs Conjugated to Therapeutic Agents and Medical Uses Thereof
US20250352490A1 (en) P-selectin targeted nanoparticles and uses thereof
WO2024254465A2 (en) Methods for promoting expansion of human cd34+ cells in vivo and for promoting neural regeneration
WO2024226686A2 (en) Aminoadipate-semialdehyde synthase inhibitors and methods of treating cancer
HK40113151A (zh) 检查点抑制剂耐药或耐药易感性的晚期/转移性癌症的改善治疗

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250124

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250124

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250124

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251223

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251223

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260130

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260130

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260130

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260212

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260212

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260212

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260302

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260302

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260302